{"id":"capeox-capecitabine","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Hand-foot skin reaction (palmar-plantar erythrodysesthesia)"},{"rate":"15-20","effect":"Diarrhea"},{"rate":"15-20","effect":"Nausea"},{"rate":"10-15","effect":"Vomiting"},{"rate":"10-15","effect":"Stomatitis"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and cellular enzymatic conversion to its active form, 5-fluorouracil (5-FU). 5-FU acts as an antimetabolite by inhibiting thymidylate synthase, blocking dTMP synthesis and thus DNA replication, while also incorporating into RNA to disrupt protein synthesis. This dual mechanism leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells.","oneSentence":"Capecitabine is a prodrug that is converted to fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell division and survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:00.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with oxaliplatin as CAPEOX)"},{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT06567782","phase":"PHASE2","title":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-02-17","conditions":"Neoplasms, Colon","enrollment":120},{"nctId":"NCT06850103","phase":"PHASE2","title":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-04-22","conditions":"Colorectal Carcinoma, Oligometastases, pMMR","enrollment":51},{"nctId":"NCT07468630","phase":"PHASE2","title":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-10","conditions":"Colon Adenocarcinoma","enrollment":106},{"nctId":"NCT07462143","phase":"PHASE2, PHASE3","title":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-04-30","conditions":"Colorectal (Colon or Rectal) Cancer","enrollment":700},{"nctId":"NCT07453875","phase":"PHASE1","title":"LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-02-09","conditions":"Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT","enrollment":9},{"nctId":"NCT05731726","phase":"PHASE2","title":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-02-22","conditions":"pMMR, MSS, MSI-L","enrollment":50},{"nctId":"NCT07448142","phase":"PHASE2","title":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT06996483","phase":"","title":"Impact of Oral Versus Intravenous 5-FU-Based Adjuvant Regimens on Sleep Quality and Depression in Patients With Gastrointestinal Cancers","status":"RECRUITING","sponsor":"Ankara Etlik City Hospital","startDate":"2025-06-05","conditions":"Gastrointestinal Neoplasms","enrollment":82},{"nctId":"NCT07184047","phase":"","title":"Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-01-15","conditions":"Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly","enrollment":72},{"nctId":"NCT07413146","phase":"NA","title":"Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Minimal Residual Disease, Immunoscore, Neoadjuvant Chemotherapy","enrollment":100},{"nctId":"NCT07113275","phase":"PHASE3","title":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-02-11","conditions":"Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy","enrollment":435},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT04854668","phase":"PHASE3","title":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-05-27","conditions":"Metastatic Colorectal Cancer","enrollment":748},{"nctId":"NCT07372300","phase":"PHASE3","title":"Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shih-Kai Hung","startDate":"2025-09-23","conditions":"Locally Advanced Rectal Carcinoma","enrollment":126},{"nctId":"NCT06864013","phase":"PHASE2","title":"SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-01-06","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":116},{"nctId":"NCT07272538","phase":"","title":"Predicting Chemotherapy Toxicity Using FRAIL and FIND in Older Adults With Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2023-12-20","conditions":"Gastrointestinal Cancers, Frailty at Older Adults, Chemotherapy","enrollment":84},{"nctId":"NCT06686576","phase":"PHASE3","title":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-12-12","conditions":"Colon Cancer","enrollment":363},{"nctId":"NCT07284992","phase":"PHASE2","title":"SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC","status":"RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2025-09-12","conditions":"Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy","enrollment":208},{"nctId":"NCT07268677","phase":"PHASE2","title":"A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.","status":"NOT_YET_RECRUITING","sponsor":"Guoxiang Cai","startDate":"2025-12-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT07239466","phase":"PHASE2","title":"A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-01","conditions":"Rectal Cancer, Radiotherapy, Immunotherapy","enrollment":48},{"nctId":"NCT06328738","phase":"PHASE1","title":"ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2024-05-30","conditions":"HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors","enrollment":275},{"nctId":"NCT03984578","phase":"PHASE2","title":"Window of Opportunity Study in Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2019-06-12","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT04703101","phase":"PHASE1","title":"Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-02-11","conditions":"Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8","enrollment":25},{"nctId":"NCT06368141","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Colon Cancer","enrollment":56},{"nctId":"NCT06884670","phase":"PHASE2","title":"Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-03-18","conditions":"Rectal Cancer","enrollment":130},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT05576480","phase":"PHASE2","title":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-02-06","conditions":"Rectal Cancer, Locally Advanced","enrollment":55},{"nctId":"NCT02008656","phase":"PHASE2","title":"Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Rectal Cancer","enrollment":358},{"nctId":"NCT05515796","phase":"PHASE2","title":"Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2022-09-01","conditions":"Immunotherapy, Gastric Cancer, Rectal Cancer","enrollment":200},{"nctId":"NCT00680901","phase":"PHASE3","title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06-04","conditions":"Neoplasms, Gastrointestinal Tract","enrollment":545},{"nctId":"NCT06865521","phase":"NA","title":"Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2025-02-21","conditions":"Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila","enrollment":22},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT04864067","phase":"PHASE2","title":"No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Servicio de Salud Metropolitano Sur Oriente","startDate":"2021-06-09","conditions":"Rectal Cancer","enrollment":73},{"nctId":"NCT06850090","phase":"PHASE3","title":"Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-30","conditions":"Rectal Cancer, Rectal Cancer Patients","enrollment":210},{"nctId":"NCT06057831","phase":"PHASE2","title":"PET/MRI in Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2026-05","conditions":"Rectal Cancer","enrollment":40},{"nctId":"NCT06209099","phase":"NA","title":"Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-01-17","conditions":"Rectal Cancer","enrollment":96},{"nctId":"NCT07007728","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-06-01","conditions":"Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver","enrollment":54},{"nctId":"NCT04566380","phase":"PHASE2","title":"ONO-4538 Phase II Rollover Study (ONO-4538-98)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-09-10","conditions":"Pan-tumor","enrollment":59},{"nctId":"NCT06157996","phase":"PHASE2","title":"Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":92},{"nctId":"NCT06718543","phase":"PHASE2","title":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"fan li","startDate":"2025-02-10","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT06621563","phase":"PHASE1","title":"Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-12-14","conditions":"Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer","enrollment":780},{"nctId":"NCT06881537","phase":"PHASE2","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06-01","conditions":"Locally Recurrent Colorectal Cancer","enrollment":15},{"nctId":"NCT05585814","phase":"PHASE2","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-05-01","conditions":"Locally Advanced Colorectal Cancer","enrollment":30},{"nctId":"NCT05216653","phase":"PHASE2","title":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)","status":"COMPLETED","sponsor":"Sir Run Run Shaw Hospital","startDate":"2022-04-07","conditions":"MSS Locally Advanced Rectal Adenocarcinoma","enrollment":32},{"nctId":"NCT06246344","phase":"","title":"Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2023-12-01","conditions":"Rectal Cancer","enrollment":128},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT05601505","phase":"PHASE2","title":"Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-02-03","conditions":"Locally Advanced Rectal Carcinoma, Circulating Tumor DNA","enrollment":470},{"nctId":"NCT06722950","phase":"PHASE2","title":"Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-12","conditions":"Colorectal Adenoma","enrollment":120},{"nctId":"NCT06709885","phase":"PHASE2","title":"HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-10-15","conditions":"Colon Adenocarcinoma","enrollment":100},{"nctId":"NCT03228043","phase":"NA","title":"Apatinib for Resectable Colorectal Cancer","status":"WITHDRAWN","sponsor":"Nanchong Central Hospital","startDate":"2020-03-01","conditions":"Apatinib, Outcome, Fatal, Colorectal Cancer","enrollment":""},{"nctId":"NCT06550453","phase":"PHASE4","title":"Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"yangjianjun","startDate":"2024-09-01","conditions":"Locally Advanced Colorectal Cancer","enrollment":20},{"nctId":"NCT06520683","phase":"PHASE3","title":"Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Colorectal Cancer, Microsatellite Instability High","enrollment":180},{"nctId":"NCT06599827","phase":"PHASE2","title":"Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-09-20","conditions":"Rectal Cancer","enrollment":54},{"nctId":"NCT06566755","phase":"PHASE3","title":"Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer","status":"RECRUITING","sponsor":"Caigang Liu","startDate":"2024-02-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT05086627","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2021-09-01","conditions":"Locally Advanced Rectal Cancer","enrollment":118},{"nctId":"NCT06516445","phase":"PHASE2","title":"SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2023-06-28","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT06504875","phase":"","title":"Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-10","conditions":"Rectal Cancer","enrollment":23},{"nctId":"NCT06504901","phase":"","title":"Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-10","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT05394740","phase":"PHASE1, PHASE2","title":"Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-06-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":30},{"nctId":"NCT06455124","phase":"PHASE2","title":"Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-05-08","conditions":"Rectal Cancer","enrollment":60},{"nctId":"NCT06443671","phase":"PHASE2, PHASE3","title":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-06-01","conditions":"Rectal Cancer","enrollment":132},{"nctId":"NCT02746796","phase":"PHASE2, PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":"Gastric Cancer","enrollment":680},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT04301557","phase":"PHASE2","title":"PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-07-31","conditions":"DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer","enrollment":25},{"nctId":"NCT06014372","phase":"PHASE2","title":"Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-01","conditions":"Colon Cancer, Neoadjuvant Therapy, Immunotherapy","enrollment":55},{"nctId":"NCT06202716","phase":"PHASE2","title":"Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-04","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT04249739","phase":"PHASE2","title":"Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2020-09-29","conditions":"Gastric Cancer","enrollment":93},{"nctId":"NCT06266832","phase":"PHASE2","title":"The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-01-01","conditions":"Rectal Adenocarcinoma","enrollment":30},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT06204484","phase":"NA","title":"MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-26","conditions":"Colorectal Cancer","enrollment":349},{"nctId":"NCT03840239","phase":"PHASE2","title":"TNT to Increase the Clinical Complete Response Rate for Distal LARC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-12-25","conditions":"Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":98},{"nctId":"NCT05307198","phase":"PHASE2","title":"Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-11","conditions":"Rectal Neoplasms","enrollment":38},{"nctId":"NCT06043999","phase":"NA","title":"Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-01","conditions":"Chemotherapy Effect, Rectal Cancer","enrollment":392},{"nctId":"NCT06035133","phase":"NA","title":"Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2023-11-10","conditions":"Rectal Cancer","enrollment":213},{"nctId":"NCT05998122","phase":"PHASE2","title":"Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2023-09-01","conditions":"Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1","enrollment":45},{"nctId":"NCT05974059","phase":"PHASE2","title":"Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-08-01","conditions":"Locally Advanced Unresectable Gastric Adenocarcinoma","enrollment":20},{"nctId":"NCT05832398","phase":"NA","title":"Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-05-01","conditions":"Colorectal Cancer","enrollment":186},{"nctId":"NCT05797467","phase":"PHASE3","title":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-04-01","conditions":"Colorectal Cancer, Chemotherapy Effect","enrollment":366},{"nctId":"NCT05640609","phase":"PHASE1, PHASE2","title":"Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2023-03-10","conditions":"Stomach Neoplasm","enrollment":57},{"nctId":"NCT05858567","phase":"PHASE2","title":"Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2023-05-11","conditions":"Rectal Cancer","enrollment":30},{"nctId":"NCT05752136","phase":"PHASE3","title":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2023-04-01","conditions":"Rectal Cancer","enrollment":108},{"nctId":"NCT05815082","phase":"PHASE3","title":"ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-02-20","conditions":"Colorectal Cancer, Liver Metastases, Circulating Tumor Cell","enrollment":490},{"nctId":"NCT05797077","phase":"PHASE3","title":"Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-02-20","conditions":"Colorectal Cancer, Liver Metastases, Circulating Tumor Cell","enrollment":346},{"nctId":"NCT05742620","phase":"NA","title":"Adjuvant Treatment of Digestive Tract Tumors","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-06-20","conditions":"Adjuvant Treatment","enrollment":100},{"nctId":"NCT04304209","phase":"PHASE2","title":"Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-10-28","conditions":"Colorectal Cancer Stage II, Colorectal Cancer Stage III","enrollment":195},{"nctId":"NCT05699746","phase":"PHASE3","title":"CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2023-03","conditions":"Colorectal Cancer","enrollment":38},{"nctId":"NCT05359393","phase":"PHASE2","title":"A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2022-12-01","conditions":"Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis","enrollment":52},{"nctId":"NCT04080843","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-11-15","conditions":"Colorectal Cancer, RAS and BRAF Wild-type, Colorectal Neoplasms","enrollment":30},{"nctId":"NCT02121405","phase":"PHASE3","title":"Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM","status":"SUSPENDED","sponsor":"Zhejiang University","startDate":"2015-10","conditions":"Colorectal Neoplasm, Effects of Radiation Therapy, Effects of Chemotherapy","enrollment":350},{"nctId":"NCT05201430","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-08-27","conditions":"Rectal Cancer","enrollment":300},{"nctId":"NCT05200299","phase":"PHASE2","title":"mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-02-01","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT05194878","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":840},{"nctId":"NCT05068206","phase":"PHASE2","title":"A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-10-08","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":120},{"nctId":"NCT04997837","phase":"PHASE3","title":"Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-07-21","conditions":"Gastric Cancer","enrollment":433},{"nctId":"NCT02860234","phase":"","title":"Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-08","conditions":"Rectal Cancer","enrollment":68},{"nctId":"NCT02864849","phase":"PHASE2","title":"Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-08","conditions":"Rectal Cancer","enrollment":81},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT02972541","phase":"NA","title":"Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2016-09-30","conditions":"Colorectal Cancer, Neoadjuvant Chemotherapy, Stent","enrollment":248},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CAPEOX/Capecitabine","genericName":"CAPEOX/Capecitabine","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted to fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell division and survival. Used for Metastatic colorectal cancer (in combination with oxaliplatin as CAPEOX), Metastatic breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}